- IBDEI0PU ; ; 01-FEB-2022
- ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
- Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
- Q Q
- ;;^UTILITY(U,$J,358.3,11616,1,4,0)
- ;;=4^I13.11
- ;;^UTILITY(U,$J,358.3,11616,2)
- ;;=^5007069
- ;;^UTILITY(U,$J,358.3,11617,0)
- ;;=I13.2^^46^563^7
- ;;^UTILITY(U,$J,358.3,11617,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11617,1,3,0)
- ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 5 Chr Kidney/ESRD
- ;;^UTILITY(U,$J,358.3,11617,1,4,0)
- ;;=4^I13.2
- ;;^UTILITY(U,$J,358.3,11617,2)
- ;;=^5007070
- ;;^UTILITY(U,$J,358.3,11618,0)
- ;;=I70.1^^46^563^3
- ;;^UTILITY(U,$J,358.3,11618,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11618,1,3,0)
- ;;=3^Atherosclerosis of Renal Artery
- ;;^UTILITY(U,$J,358.3,11618,1,4,0)
- ;;=4^I70.1
- ;;^UTILITY(U,$J,358.3,11618,2)
- ;;=^269760
- ;;^UTILITY(U,$J,358.3,11619,0)
- ;;=I77.3^^46^563^2
- ;;^UTILITY(U,$J,358.3,11619,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11619,1,3,0)
- ;;=3^Arterial Fibromuscular Dysplasia
- ;;^UTILITY(U,$J,358.3,11619,1,4,0)
- ;;=4^I77.3
- ;;^UTILITY(U,$J,358.3,11619,2)
- ;;=^5007812
- ;;^UTILITY(U,$J,358.3,11620,0)
- ;;=E26.02^^46^563^5
- ;;^UTILITY(U,$J,358.3,11620,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11620,1,3,0)
- ;;=3^Glucocorticoid-Remediable Aldosteronism
- ;;^UTILITY(U,$J,358.3,11620,1,4,0)
- ;;=4^E26.02
- ;;^UTILITY(U,$J,358.3,11620,2)
- ;;=^329904
- ;;^UTILITY(U,$J,358.3,11621,0)
- ;;=I12.9^^46^563^14
- ;;^UTILITY(U,$J,358.3,11621,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11621,1,3,0)
- ;;=3^Hypertensive CKD Stage 1-4
- ;;^UTILITY(U,$J,358.3,11621,1,4,0)
- ;;=4^I12.9
- ;;^UTILITY(U,$J,358.3,11621,2)
- ;;=^5007066
- ;;^UTILITY(U,$J,358.3,11622,0)
- ;;=I12.0^^46^563^15
- ;;^UTILITY(U,$J,358.3,11622,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11622,1,3,0)
- ;;=3^Hypertensive CKD Stage 5 or ESRD
- ;;^UTILITY(U,$J,358.3,11622,1,4,0)
- ;;=4^I12.0
- ;;^UTILITY(U,$J,358.3,11622,2)
- ;;=^5007065
- ;;^UTILITY(U,$J,358.3,11623,0)
- ;;=I13.0^^46^563^6
- ;;^UTILITY(U,$J,358.3,11623,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11623,1,3,0)
- ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 1-4 Chr Kidney
- ;;^UTILITY(U,$J,358.3,11623,1,4,0)
- ;;=4^I13.0
- ;;^UTILITY(U,$J,358.3,11623,2)
- ;;=^5007067
- ;;^UTILITY(U,$J,358.3,11624,0)
- ;;=I13.10^^46^563^9
- ;;^UTILITY(U,$J,358.3,11624,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11624,1,3,0)
- ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 1-4 Chr Kidney
- ;;^UTILITY(U,$J,358.3,11624,1,4,0)
- ;;=4^I13.10
- ;;^UTILITY(U,$J,358.3,11624,2)
- ;;=^5007068
- ;;^UTILITY(U,$J,358.3,11625,0)
- ;;=I15.1^^46^563^11
- ;;^UTILITY(U,$J,358.3,11625,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11625,1,3,0)
- ;;=3^Hypertension Secondary to Oth Renal Disorders
- ;;^UTILITY(U,$J,358.3,11625,1,4,0)
- ;;=4^I15.1
- ;;^UTILITY(U,$J,358.3,11625,2)
- ;;=^5007072
- ;;^UTILITY(U,$J,358.3,11626,0)
- ;;=I15.2^^46^563^10
- ;;^UTILITY(U,$J,358.3,11626,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11626,1,3,0)
- ;;=3^Hypertension Secondary to Endocrine Disorders
- ;;^UTILITY(U,$J,358.3,11626,1,4,0)
- ;;=4^I15.2
- ;;^UTILITY(U,$J,358.3,11626,2)
- ;;=^5007073
- ;;^UTILITY(U,$J,358.3,11627,0)
- ;;=I50.1^^46^563^16
- ;;^UTILITY(U,$J,358.3,11627,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11627,1,3,0)
- ;;=3^Left Ventricular Failure
- ;;^UTILITY(U,$J,358.3,11627,1,4,0)
- ;;=4^I50.1
- ;;^UTILITY(U,$J,358.3,11627,2)
- ;;=^5007238
- ;;^UTILITY(U,$J,358.3,11628,0)
- ;;=E26.09^^46^563^17
- ;;^UTILITY(U,$J,358.3,11628,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11628,1,3,0)
- ;;=3^Primary Hyperaldosteronism,Other
- ;;^UTILITY(U,$J,358.3,11628,1,4,0)
- ;;=4^E26.09
- --- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0PU 3783 printed Feb 18, 2025@23:19:48 Page 2
- IBDEI0PU ; ; 01-FEB-2022
- +1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
- +2 if 'DIFQR(358.3)
- QUIT
- FOR I=1:2
- SET X=$TEXT(Q+I)
- if X=""
- QUIT
- SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
- SET X=$EXTRACT(X,4,999)
- if $ASCII(Y)=126
- SET I=I+1
- SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
- if $ASCII(Y)=61
- SET Y=$EXTRACT(Y,2,999)
- XECUTE NO
- IF '$TEST
- SET @X=Y
- Q QUIT
- +1 ;;^UTILITY(U,$J,358.3,11616,1,4,0)
- +2 ;;=4^I13.11
- +3 ;;^UTILITY(U,$J,358.3,11616,2)
- +4 ;;=^5007069
- +5 ;;^UTILITY(U,$J,358.3,11617,0)
- +6 ;;=I13.2^^46^563^7
- +7 ;;^UTILITY(U,$J,358.3,11617,1,0)
- +8 ;;=^358.31IA^4^2
- +9 ;;^UTILITY(U,$J,358.3,11617,1,3,0)
- +10 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 5 Chr Kidney/ESRD
- +11 ;;^UTILITY(U,$J,358.3,11617,1,4,0)
- +12 ;;=4^I13.2
- +13 ;;^UTILITY(U,$J,358.3,11617,2)
- +14 ;;=^5007070
- +15 ;;^UTILITY(U,$J,358.3,11618,0)
- +16 ;;=I70.1^^46^563^3
- +17 ;;^UTILITY(U,$J,358.3,11618,1,0)
- +18 ;;=^358.31IA^4^2
- +19 ;;^UTILITY(U,$J,358.3,11618,1,3,0)
- +20 ;;=3^Atherosclerosis of Renal Artery
- +21 ;;^UTILITY(U,$J,358.3,11618,1,4,0)
- +22 ;;=4^I70.1
- +23 ;;^UTILITY(U,$J,358.3,11618,2)
- +24 ;;=^269760
- +25 ;;^UTILITY(U,$J,358.3,11619,0)
- +26 ;;=I77.3^^46^563^2
- +27 ;;^UTILITY(U,$J,358.3,11619,1,0)
- +28 ;;=^358.31IA^4^2
- +29 ;;^UTILITY(U,$J,358.3,11619,1,3,0)
- +30 ;;=3^Arterial Fibromuscular Dysplasia
- +31 ;;^UTILITY(U,$J,358.3,11619,1,4,0)
- +32 ;;=4^I77.3
- +33 ;;^UTILITY(U,$J,358.3,11619,2)
- +34 ;;=^5007812
- +35 ;;^UTILITY(U,$J,358.3,11620,0)
- +36 ;;=E26.02^^46^563^5
- +37 ;;^UTILITY(U,$J,358.3,11620,1,0)
- +38 ;;=^358.31IA^4^2
- +39 ;;^UTILITY(U,$J,358.3,11620,1,3,0)
- +40 ;;=3^Glucocorticoid-Remediable Aldosteronism
- +41 ;;^UTILITY(U,$J,358.3,11620,1,4,0)
- +42 ;;=4^E26.02
- +43 ;;^UTILITY(U,$J,358.3,11620,2)
- +44 ;;=^329904
- +45 ;;^UTILITY(U,$J,358.3,11621,0)
- +46 ;;=I12.9^^46^563^14
- +47 ;;^UTILITY(U,$J,358.3,11621,1,0)
- +48 ;;=^358.31IA^4^2
- +49 ;;^UTILITY(U,$J,358.3,11621,1,3,0)
- +50 ;;=3^Hypertensive CKD Stage 1-4
- +51 ;;^UTILITY(U,$J,358.3,11621,1,4,0)
- +52 ;;=4^I12.9
- +53 ;;^UTILITY(U,$J,358.3,11621,2)
- +54 ;;=^5007066
- +55 ;;^UTILITY(U,$J,358.3,11622,0)
- +56 ;;=I12.0^^46^563^15
- +57 ;;^UTILITY(U,$J,358.3,11622,1,0)
- +58 ;;=^358.31IA^4^2
- +59 ;;^UTILITY(U,$J,358.3,11622,1,3,0)
- +60 ;;=3^Hypertensive CKD Stage 5 or ESRD
- +61 ;;^UTILITY(U,$J,358.3,11622,1,4,0)
- +62 ;;=4^I12.0
- +63 ;;^UTILITY(U,$J,358.3,11622,2)
- +64 ;;=^5007065
- +65 ;;^UTILITY(U,$J,358.3,11623,0)
- +66 ;;=I13.0^^46^563^6
- +67 ;;^UTILITY(U,$J,358.3,11623,1,0)
- +68 ;;=^358.31IA^4^2
- +69 ;;^UTILITY(U,$J,358.3,11623,1,3,0)
- +70 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 1-4 Chr Kidney
- +71 ;;^UTILITY(U,$J,358.3,11623,1,4,0)
- +72 ;;=4^I13.0
- +73 ;;^UTILITY(U,$J,358.3,11623,2)
- +74 ;;=^5007067
- +75 ;;^UTILITY(U,$J,358.3,11624,0)
- +76 ;;=I13.10^^46^563^9
- +77 ;;^UTILITY(U,$J,358.3,11624,1,0)
- +78 ;;=^358.31IA^4^2
- +79 ;;^UTILITY(U,$J,358.3,11624,1,3,0)
- +80 ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 1-4 Chr Kidney
- +81 ;;^UTILITY(U,$J,358.3,11624,1,4,0)
- +82 ;;=4^I13.10
- +83 ;;^UTILITY(U,$J,358.3,11624,2)
- +84 ;;=^5007068
- +85 ;;^UTILITY(U,$J,358.3,11625,0)
- +86 ;;=I15.1^^46^563^11
- +87 ;;^UTILITY(U,$J,358.3,11625,1,0)
- +88 ;;=^358.31IA^4^2
- +89 ;;^UTILITY(U,$J,358.3,11625,1,3,0)
- +90 ;;=3^Hypertension Secondary to Oth Renal Disorders
- +91 ;;^UTILITY(U,$J,358.3,11625,1,4,0)
- +92 ;;=4^I15.1
- +93 ;;^UTILITY(U,$J,358.3,11625,2)
- +94 ;;=^5007072
- +95 ;;^UTILITY(U,$J,358.3,11626,0)
- +96 ;;=I15.2^^46^563^10
- +97 ;;^UTILITY(U,$J,358.3,11626,1,0)
- +98 ;;=^358.31IA^4^2
- +99 ;;^UTILITY(U,$J,358.3,11626,1,3,0)
- +100 ;;=3^Hypertension Secondary to Endocrine Disorders
- +101 ;;^UTILITY(U,$J,358.3,11626,1,4,0)
- +102 ;;=4^I15.2
- +103 ;;^UTILITY(U,$J,358.3,11626,2)
- +104 ;;=^5007073
- +105 ;;^UTILITY(U,$J,358.3,11627,0)
- +106 ;;=I50.1^^46^563^16
- +107 ;;^UTILITY(U,$J,358.3,11627,1,0)
- +108 ;;=^358.31IA^4^2
- +109 ;;^UTILITY(U,$J,358.3,11627,1,3,0)
- +110 ;;=3^Left Ventricular Failure
- +111 ;;^UTILITY(U,$J,358.3,11627,1,4,0)
- +112 ;;=4^I50.1
- +113 ;;^UTILITY(U,$J,358.3,11627,2)
- +114 ;;=^5007238
- +115 ;;^UTILITY(U,$J,358.3,11628,0)
- +116 ;;=E26.09^^46^563^17
- +117 ;;^UTILITY(U,$J,358.3,11628,1,0)
- +118 ;;=^358.31IA^4^2
- +119 ;;^UTILITY(U,$J,358.3,11628,1,3,0)
- +120 ;;=3^Primary Hyperaldosteronism,Other
- +121 ;;^UTILITY(U,$J,358.3,11628,1,4,0)
- +122 ;;=4^E26.09